Price$0.75-4.35 (-85.30%)
2026-03-192026-06-23
News · 26 weeks68-71%
2025-12-282026-06-21
Mix3990d
- SEC Filings17(44%)
- Other15(38%)
- Insider4(10%)
- Offering3(8%)
Latest news
25 items- SECFibroBiologics Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits8-K - FibroBiologics, Inc. (0001958777) (Filer)
- PRFibroBiologics Receives Notice of Allowance for U.S. Patent Covering Topical Fibroblast Spheroid Therapy for Wound HealingHOUSTON, June 22, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (NASDAQ:FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for the Company’s patent application entitled "Therapeutic Use of Fibroblasts in Wound Healing." The allowed application, U.S. Patent Application No. 18/184,726, contains 19 allowed claims directed to methods of treating and accelerating the healing of wounds by topically a
- PRFibroBiologics Advances Patient Dosing for Phase 1/2 Clinical Trial of CYWC628 for the Treatment of Diabetic Foot UlcersHOUSTON, June 16, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (NASDAQ:FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, announced that the first patients have been dosed in the Company's Phase 1/2 clinical trial evaluating CYWC628 for the treatment of diabetic foot ulcers (DFUs). Initial dosing took place during the week of June 1, 2026. In parallel with clinical progress, FibroBiologics continues to advance manufacturing of CYWC628 to support ongoing trial activity. Drug product from the Company'
- PRFibroBiologics Announces First Patients Dosed in Phase 1/2 Clinical Trial Evaluating CYWC628 for the Treatment of Diabetic Foot UlcersHOUSTON, June 03, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (NASDAQ:FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that the first patients have been enrolled and dosed in the Company's Phase 1/2 clinical trial evaluating CYWC628 for the treatment of diabetic foot ulcers (DFUs). A Media Snippet accompanying this announcement is available by clicking on this link. The prospective, multicenter, randomized study is being conducted across multiple sites in Australia following re
- PRFibroBiologics Presents Preclinical Data Demonstrating Durable Immunomodulation in Psoriasis at the Society for Investigative Dermatology 2026 Annual MeetingHOUSTON, May 22, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (NASDAQ:FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced preclinical data from its CYPS317 program for psoriasis presented at the Society for Investigative Dermatology 2026 Annual Meeting, held May 13-15, 2026, in Chicago, Illinois. A link to the poster can be found here. Psoriasis is a chronic inflammatory skin disease driven by dysregulated innate and adaptive immunity, with the IL-23/Th17 axis playing a central role
- PRFibroBiologics Files Patent Application for Oral Administration of Fibroblast TherapeuticsHOUSTON, May 18, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (NASDAQ:FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 270+ patents issued and pending focused on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced the filing of a new provisional patent application with the U.S. Patent and Trademark Office (USPTO) titled "Oral Fibroblasts and Fibroblast-Derived Therapeutics and Delivery Systems for Same" covering oral delivery systems designed to protect fibroblast-based therapeutics through the stomach and enable targeted release in the gastrointestinal tract. The provisional pat
- PRFibroBiologics Advancing Development of a Fibroblast Treatment for HantavirusHOUSTON, May 11, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (NASDAQ:FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 270+ patents issued and pending focused on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced a strategic expansion of its fibroblast-based platform to target Hantavirus. Building on existing preclinical work in treating acute respiratory distress syndrome (ARDS), the major cause of lethality in COVID-19 patients, FibroBiologics is expanding its therapeutic platform to encompass Hantavirus pulmonary syndrome (HPS), which causes similar terminal lung damage and in
- SECFibroBiologics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits8-K - FibroBiologics, Inc. (0001958777) (Filer)
- PRFibroBiologics CEO Issues Letter to ShareholdersHOUSTON, May 05, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (NASDAQ:FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today issued the following letter to shareholders. Dear Fellow Shareholders, This year, FibroBiologics achieved a milestone we have been working toward over the past few years. We initiated our clinical trial for our lead program, CYWC628, an investigational fibroblast-based therapy for diabetic foot ulcers (DFUs). After years of building the technology and infrastructure to sup
- SECFibroBiologics Inc. filed SEC Form 8-K: Leadership Update8-K - FibroBiologics, Inc. (0001958777) (Filer)
- SECSEC Form DEFA14A filed by FibroBiologics Inc.DEFA14A - FibroBiologics, Inc. (0001958777) (Filer)
- SECSEC Form DEF 14A filed by FibroBiologics Inc.DEF 14A - FibroBiologics, Inc. (0001958777) (Filer)
- INSIDERSEC Form 4 filed by CHIEF EXECUTIVE OFFICER O'Heeron Pete4 - FibroBiologics, Inc. (0001958777) (Issuer)
- INSIDERSEC Form 4 filed by Chief Scientific Officer Khoja Hamid4 - FibroBiologics, Inc. (0001958777) (Issuer)
- INSIDERSEC Form 4 filed by Chief Financial Officer Davis Jason4 - FibroBiologics, Inc. (0001958777) (Issuer)
- INSIDERSEC Form 4 filed by General Counsel Garcia Ruben A4 - FibroBiologics, Inc. (0001958777) (Issuer)
- PRFibroBiologics Reports Preclinical Data Showing Fibroblast Spheroids May Actively Reprogram the Burn Wound Environment to Drive Healing and Reduce ScarringHOUSTON, May 04, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (NASDAQ:FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced compelling preclinical results suggesting that topical treatment with human dermal fibroblast (HDF) spheroids may reprogram the burn wound environment by dampening harmful inflammation, reshaping immune cell behavior, and reducing markers of scar-forming activity, within just eight days of injury. In the study, daily treatments with HDF spheroids per wound were ini
- PRFibroBiologics Announces Release of CYWC628 Drug Product for Phase 1/2 Diabetic Foot Ulcer Clinical TrialHOUSTON, May 04, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (NASDAQ:FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced the release of the first batch of its CYWC628 drug product to support its Phase 1/2 clinical trial in patients with diabetic foot ulcers (DFUs). The CYWC628 drug product was manufactured in accordance with the U.S. Food and Drug Administration's current Good Manufacturing Practices (cGMP) and has successfully passed all required safety and quality testing, enabling
- SECSEC Form 424B5 filed by FibroBiologics Inc.424B5 - FibroBiologics, Inc. (0001958777) (Filer)
- SECFibroBiologics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits8-K - FibroBiologics, Inc. (0001958777) (Filer)
- PRFibroBiologics Reports Q1 2026 Financial Results and Provides Corporate UpdateHOUSTON, April 30, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (NASDAQ:FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today reported financial results for the first quarter ended March 31, 2026, and provided a corporate update. Recent Highlights Completed manufacturing of the first two batches of the CYWC628 drug product in accordance with Food & Drug Administration (FDA) Good Manufacturing Practices (cGMP) for the phase 1/2 clinical trial for the treatment of diabetic foot ulcers (DFUs).Comp
- SECSEC Form 10-Q filed by FibroBiologics Inc.10-Q - FibroBiologics, Inc. (0001958777) (Filer)
- PRFibroBiologics Announces Poster Presentation at the Society for Investigative Dermatology Annual Meeting 2026HOUSTON, April 30, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (NASDAQ:FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced the presentation of preclinical data from its CYPS317 program for psoriasis at the Society for Investigative Dermatology 2026 Annual Meeting taking place May 13-15, 2026, in Chicago, Illinois. Details of the presentations are as follows:Event: Society for Investigative Dermatology 2026 Annual MeetingPresenter: Chuo Fang, MD, Ph.D., Senior Scientist at FibroBiolog
- SECSEC Form PRE 14A filed by FibroBiologics Inc.PRE 14A - FibroBiologics, Inc. (0001958777) (Filer)
- SECFibroBiologics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - FibroBiologics, Inc. (0001958777) (Filer)
FBLG FAQ
5 questionsWhere does FBLG stock trade?
FibroBiologics Inc. (FBLG) is listed on NASDAQ.What sector and industry is FBLG in?
FibroBiologics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What are analysts saying about FBLG?
FibroBiologics Inc. has had 3 recent analyst actions on file. The most recent action was from Rodman & Renshaw: Buy with a $1200.00 price target on 2024-12-12. Recent price targets cluster around $1200.00.What companies are similar to FBLG?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), AZN (AstraZeneca PLC), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare FBLG side-by-side with any of them on Quantisnow.How can I track FBLG on Quantisnow?
Quantisnow aggregates FibroBiologics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow FBLG to receive live email and push alerts on every new disclosure.